26th week of 2016 patent applcation highlights part 9 |
Patent application number | Title | Published |
20160184251 | CRYSTALLINE POLYMORPHIC FORMS OF MONOSODIUM N-[-8-(2-HYDROXYBENZOYL)AMINO]CAPRYLATE - The present invention relates to crystalline polymorphic forms of monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate (“SNAC”), including two hydrates, a methanol solvate, and an ethanol solvate, of SNAC. More specifically, the present invention provide six polymorphic forms of SNAC (hereafter referred to as Forms I-VI). The present invention also provides an amorphous form of SNAC. | 2016-06-30 |
20160184252 | COMPOSITIONS COMPRISING 15-HEPE AND METHODS OF TREATING OR PREVENTING FIBROSIS USING SAME - The present disclosure provides compositions comprising 15-HEPE and methods of using same for treating and/or preventing fibrosis in a subject in need thereof. | 2016-06-30 |
20160184253 | HIGH PENETRATION PRODRUG COMPOSITIONS OF RETINOIDS AND RETINOID-RELATED COMPOUNDS - The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of retinoids and retinoid-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate. | 2016-06-30 |
20160184254 | COMPOSITIONS COMPRISING VITAMIN K DERIVATIVES AND SALTS - This application relates to new formulations of vitamin K1 and K2 provitamins. These formulations can be used as nutraceuticals, e.g. for the fortification of foods or simply in supplements or can be used in pharmaceuticals for the treatment of a variety of conditions known to benefit from the administration of vitamin K1 and K2. | 2016-06-30 |
20160184255 | COMPOUNDS FOR TREATING INFLAMMATION AND PAIN - The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ω-(methylthio)alkylnitriles such as 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. | 2016-06-30 |
20160184256 | METHOD OF TREATING DISORDERS OF THE CARDIOVASCULAR SYSTEM AND A PHARMACEUTICAL AGENT - A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. | 2016-06-30 |
20160184257 | ANTIFUGETACTIC AGENTS FOR THE TREAMENT OF PANCREAS CANCER - This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response. | 2016-06-30 |
20160184258 | ORAL GASTROINTESTINAL DOSAGE FORM DELIVERY SYSTEM OF CANNABINOIDS AND/OR STANDARDIZED MARIJUANA EXTRACTS - An oral gastrointestinal dosage form of cannabinoids and/or standardized marijuana extracts in a self-emulsifying system operable to avoid hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery for promoting lymphatic transport. The oral gastrointestinal dosage form includes: (a) a pharmacologically active form of cannabinoids and/or standardized marijuana extracts; and (b) an oily medium consisting of: (i) one or more triglycerides formed from long chain fatty having from C | 2016-06-30 |
20160184259 | OPHTHALMIC SOLUTIONS FOR GLAUCOMA AND CONJUNCTIVITIS TREATMENT - This invention generally relates to an ophthalmic solution comprising cannabinoids for the treatment of glaucoma. Also disclosed is an ophthalmic solution comprising cannabinoids for symptomatic relief of conjunctival inflammation. Cannabinoids are selected to achieve the specific purpose of the respective ophthalmic solution. | 2016-06-30 |
20160184260 | METHODS FOR PURIFYING TRANS-(-)-DELTA9-TETRAHYDROCANNABINOL AND TRANS-(+)-DELTA9-TETRAHYDROCANNABINOL - Methods for making trans-(−)-Δ | 2016-06-30 |
20160184261 | METHODS FOR PURIFYING TRANS-(-)-DELTA9-TETRAHYDROCANNABINOL AND TRANS-(+)-DELTA9-TETRAHYDROCANNABINOL - Methods for making trans-(−)-Δ | 2016-06-30 |
20160184262 | 4-METHYLUMBELLIFERONE TREATMENT FOR IMMUNE MODULATION - Compositions for treating autoimmune, allergic, or atopic disease comprising a compound that inhibits hyaluronan synthesis and a pharmaceutically acceptable carrier are described. In some embodiments, the compound that inhibits hyaluronan synthesis is 4-methylumbelliferone or a metabolite of 4-methylumbelliferone. Methods for treating autoimmune diabetes, multiple sclerosis and/or autoimmune demyelination, including administering to the subject a composition having a compound in an amount effective to inhibit hyaluronan synthesis in a mammalian subject, are also described. | 2016-06-30 |
20160184263 | Compositions - The invention provides a colon cleansing solution comprising: | 2016-06-30 |
20160184264 | MICROCAPSULES CONTAINING AN OXIDIZABLE ACTIVE, AND A PROCESS FOR PREPARING THE SAME - Disclosed is a microcapsule including a core having an oxidizable active (OA), the outer part of said core being in a solid form, and a water insoluble coating obtained from an encapsulating agent (EA), with the coating surrounding said core. In particular, the EA can be water soluble or organic solvent soluble, in particular in ethanol. The microcapsule can also include an EA in which the water solubility is pH-dependent. Also, the core does not contain a metal oxide, and the coating does not include a disintegrant, such as sodium starch glycolate. Also disclosed is a process for preparing the microcapsules. | 2016-06-30 |
20160184265 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS - The present invention relates to compounds of formula I: | 2016-06-30 |
20160184266 | COMPOSITION AND METHOD FOR TREATMENT OF DIABETES - The present invention relates to a method of treating diabetes type II by delivery of butyric acid, bile acid, long chain fatty acid or glutamine to the colon by bypassing the upper digestive tract. The composition is combined either by the same or different route of administration with a DPP-IV inhibitor such as vildagliptin. | 2016-06-30 |
20160184267 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF - Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. | 2016-06-30 |
20160184268 | COMPOSITIONS OF ELTROMBOPAG - The present invention relates to compositions of eltrombopag olamine. The present invention also relates to process for preparing compositions comprising eltrombopag olamine. | 2016-06-30 |
20160184269 | DENTAL ANESTHETIC COMPRISING TETRACAINE AND A VASOCONSTRICTOR FOR INTRANASAL ADMINISTRATION - The present invention relates to tetracaine based anesthetic formulations and methods of use thereof. The invention further relates to topical formulations of tetracaine and methods of topically anesthetizing body tissues. The present invention also relates to tetracaine based dental anesthetic formulations and methods for anesthetizing the maxillary dental arch using these formulations. | 2016-06-30 |
20160184270 | SUBSTITUTED 2-IMIDAZOLIDINONES AND 2-IMIDAZOLONES AND THEIR USE IN THE TREATMENT OF CANCER - Compounds of formula (I) wherein R | 2016-06-30 |
20160184271 | Amino Acid Composition for Use in the Treatment of a PDD - The invention relates to the use of at least one amino acid, selected from the group of histidine, lysine, and threonine in the manufacture of a composition for use in the treatment of a pervasive development disorder, a neurogenetic syndrome associated with a pervasive development disorder or a symptom of a pervasive development disorder. The invention further relates to a food product comprising histidine, lysine, and/or threonine, to a supplement comprising histidine, lysine, and/or threonine and to a kit of parts comprising histidine, lysine, and/or threonine. | 2016-06-30 |
20160184272 | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation - A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that demonstrates substantial agonist activity at alpha adrenergic receptors and that is selected for peripheral (local) vasoconstriction and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents. | 2016-06-30 |
20160184273 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS - The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy. | 2016-06-30 |
20160184274 | Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition - Methods of using inhibitors of Goodpasture Antigen Binding Protein for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition (EMT), treating an invasive tumor, and detecting EMT in a tissue are described. | 2016-06-30 |
20160184275 | PHARMACEUTICAL COMPOSITION FOR MODIFIED USE - A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed. | 2016-06-30 |
20160184276 | Sphingosine kinase inhibition for the treatment and prevention of obstetrical disorders - The subject invention is directed to the treatment of obstetrical disorders by administration of a sphingosine kinase inhibitor. Spingosine kinase inhibitors are useful in the management or treatment of obstetrical disorders resulting from inflammation such as preterm birth and preterm labor. The treatment may take a variety of forms and is intended for a variety of mammals, such as premature neonates to adult humans. | 2016-06-30 |
20160184277 | Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase Activator - The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator. | 2016-06-30 |
20160184278 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE VASCULAR DISORDERS - The technology described herein is directed to methods and compositions for the treatment of proliferative vascular disorders, e.g. hemangioma. In some aspects, the methods and compositions described herein related to a mTOR inhibitor or nifedipine. | 2016-06-30 |
20160184279 | METHODS OF TREATING PAIN AND/OR ITCH WITH SMALL MOLECULE INHIBITORS TARGETING AN mTOR PATHWAY - Methods of treating pain and/or itch in a targeted region of a subject and compositions and dosage forms therefor are described herein. Such methods can include topically administering a therapeutically effective amount of an mTOR pathway inhibitor to the subject. | 2016-06-30 |
20160184280 | METHODS OF PREVENTING THE DEVELOPMENT OF MUCOSITIS AND RELATED DISORDERS - Disclosed is a method of preventing the development of mucositis in a subject undergoing radiation therapy or chemotherapy for a disease in need thereof comprising administering an effective amount of a mammalian target of rapamycin (mTOR) inhibitor, such as rapamycin, to the subject. Further disclosed is a method of increasing the lifespan of a normal oral keratinocyte and/or reducing oxidative stress in a normal epithelial cell, wherein the method comprises administering an effective amount of an mTOR inhibitor to a subject undergoing radiation therapy or chemotherapy for a disease in need thereof. | 2016-06-30 |
20160184281 | NAMPT INHIBITORS - Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. | 2016-06-30 |
20160184282 | NAMPT INHIBITORS - Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. | 2016-06-30 |
20160184283 | ANTIBACTERIAL COMPOUNDS - Disclosed are compounds of formula (I): | 2016-06-30 |
20160184284 | LIQUID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING FEXOFENADINE - The present invention relates to a liquid pharmaceutical composition for oral administration comprising fexofenadine and/or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier which is either polyethylene glycol or a propylene glycol-based solvent, or a mixture thereof, from 35 to 90% wt. of a pharmaceutical excipient stabilizing fexofenadine and/or a pharmaceutically acceptable salt thereof, said pharmaceutical excipient consisting of glycerol with optionally sorbitol. The invention also relates to the uses of these compositions as a medicament and to the process for preparing said compositions. | 2016-06-30 |
20160184285 | PIPERIDINE UREA DERIVATIVES - Compounds of the formula I | 2016-06-30 |
20160184286 | DURABLE TREATMENT WITH 4-AMINOPYRIDINE IN PATIENTS WITH DEMYELINATION - Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as MS. | 2016-06-30 |
20160184287 | TREATMENT FOR NICOTINE-INDUCED LUNG DISEASE USING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AGONISTS - This invention pertains to the discovery that nicotine interrupts molecular signaling between endodermal and mesodermal cells of the lung alveolus. Treatment of the lung with specific molecular agents (e.g., PPAR gamma agonists) can prevent and/or reverse the injury caused by nicotine. | 2016-06-30 |
20160184288 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS - The invention relates to compounds of formula I: | 2016-06-30 |
20160184289 | COMPOSITIONS CONTAINING AROMATIC ALDEHYDES AND THEIR USE IN TREATMENTS - Disclosed are pharmaceutical and cosmetic compositions containing aromatic aldehyde compounds. Some of the disclosed compositions are useful as topical therapeutics for treating inflammatory dermatologic conditions. Some of the compositions are useful in transdermal and other systemic dose forms for treating other inflammatory conditions in mammals. | 2016-06-30 |
20160184290 | METHOD OF TREATING SCHIZOPHRENIA - A method of treating symptoms of schizophrenia includes enterically administering to a subject a pharmacological agent that inhibits presynaptic glutamate release, modulates postsynaptic glutamate response, or both. | 2016-06-30 |
20160184291 | TREATMENT FOR COLLAPSING TRACHEA - The present invention provides pharmaceutical methods and formulations for treating collapsing trachea and related disorders. | 2016-06-30 |
20160184292 | SUBLINGUAL AND BUCCAL FILM COMPOSITIONS - The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent. | 2016-06-30 |
20160184293 | A COMBINATION OF OXYCODONE AND NALOXONE FOR USE IN TREATING PAIN IN PATIENTS SUFFERING FROM PAIN AND A DISEASE RESULTING IN INTESTINAL DYSBIOSIS AND/OR INCREASING THE RISK FOR INTESTINAL BACTERIAL TRANSLOCATION - The present invention is concerned with an oral pharmaceutical dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain in patients suffering from i) pain and at least one further disease ii), wherein said at least one further disease ii) results in intestinal dysbiosis, or for use in the treatment of pain in patients suffering from i) pain and at least one further disease iii), wherein said at least one further disease iii) increases the risk for intestinal bacterial translocation and thus for peritonitis, SIRS and/or sepsis. | 2016-06-30 |
20160184294 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE - Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided. | 2016-06-30 |
20160184296 | COMPOSITIONS COMPRISING BUPRENORPHINE - This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof. | 2016-06-30 |
20160184297 | CRUSH RESISTANT DELAYED-RELEASE DOSAGE FORMS - The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed. | 2016-06-30 |
20160184298 | INHIBITORS AND ENHANCERS OF URIDINE DIPHOSPHATE-GLUCURONOSYLTRANSFERASE 2B (UGT2B) - A UGT2B inhibitor capable of increasing the bio-availability of a drug, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin,β-naphthoflavone, α-naphthoflavone, hesperetin, terpineol, (+)-limonene, β-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ® 58, BRIJ® 76, Pluronic® F68, Pluronic® F127, and a combination thereof. A UGT2B enhancer capable of enhancing a clearance rate of morphine-like analgesic agents, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: nordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol, formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin, naringenin, daidzin, (−)-epicatechin, luteolin-7-glucoside, ergosterol, rutin, luteolin, ethyl myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, trans-cinnamaldehyde, and a combination thereof. | 2016-06-30 |
20160184299 | COMBINATION COMPOSITION COMPRISING OXYCODONE AND ACETAMINOPHEN FOR RAPID ONSET AND EXTENDED DURATION OF ANALGESIA - The present disclosure provides an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof. | 2016-06-30 |
20160184300 | COMPOSITION CONTAINING A DPP-IV INHIBITOR FOR PREVENTING OR TREATING RENAL DISEASES - The present invention relates to a composition for preventing or treating renal diseases. The composition of the present invention improves lipid metabolism, prevents histological damage including renal fibrosis, alleviates microalbuminuria, and maintains nephrons of renal glomeruli. Therefore, the composition is useful for treating renal diseases. | 2016-06-30 |
20160184301 | LIPID-BASED COMPOSITIONS OF ANTIINFECTIVES FOR TREATING PULMONARY INFECTIONS AND METHODS OF USE THEREOF - A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed. | 2016-06-30 |
20160184302 | LIPID-BASED COMPOSITIONS OF ANTIINFECTIVES FOR TREATING PULMONARY INFECTIONS AND METHODS OF USE THEREOF - A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed. | 2016-06-30 |
20160184303 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS - The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration. | 2016-06-30 |
20160184304 | COMPOSITION FOR REDUCING NERVOUS SYSTEM INJURY AND METHOD OF MAKING AND USE THEREOF - This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof. | 2016-06-30 |
20160184305 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS - The present invention provides a compound of formula IA or a pharmaceutically acceptable salt thereof; 5 (IA) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 2016-06-30 |
20160184306 | Novel Pyrimidinyl-DiazoSpiro Compounds - The invention relates to spiro derivatives, to the use of said derivatives in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivatives and processes for their preparation. | 2016-06-30 |
20160184307 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors - The present invention relates to compounds of formula (I) | 2016-06-30 |
20160184308 | AMINOPYRIMIDINE DERIVATIVES FOR USE AS MODULATORS OF KINASE ACTIVITY - The invention provides novel heterocyclic amine compounds according to Formula (I) and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 2016-06-30 |
20160184309 | METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS - This application describes the use of the compound (I) or a salt thereof, either alone or in combination with other therapeutically active agents, for the treatment of particular cancers, including any solid or hematological cancer in which AXL or c-Met is over-expressed. | 2016-06-30 |
20160184310 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES - Compounds of the formula I | 2016-06-30 |
20160184311 | Combination Therapy for the Treatment of Cancer - The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof. | 2016-06-30 |
20160184312 | TRANSDERMAL ADMINISTRATION SYSTEM FOR USE IN THE TREATMENT OF CHRONIC BRONCHOPULMONARY DISEASES - Transdermal administration system comprising doxofylline as the active ingredient, for use in the treatment of bronchopulmonary diseases having a broncho-obstructive component. | 2016-06-30 |
20160184313 | Drug Combinations and Uses in Treating a Coughing Condition - The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions. | 2016-06-30 |
20160184314 | Drug Combinations and Uses in Treating a Coughing Condition - The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions. | 2016-06-30 |
20160184315 | METHOD OF IMPROVING COGNITION AND SOCIAL BEHAVIOR IN HUMANS HAVING DEFICITS THEREIN DUE TO NEURODEGENERATIVE DISORDERS AND COMPOUNDS AND COMPOSITIONS THEREFOR | 2016-06-30 |
20160184316 | NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula: | 2016-06-30 |
20160184317 | Aminopyridine Derived Compounds as LRRK2 Inhibitors - The present invention is directed to aminopyridine derived compounds of formula (A) | 2016-06-30 |
20160184318 | AUTOTAXIN INHIBITORS - The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin. | 2016-06-30 |
20160184319 | Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias - The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL. | 2016-06-30 |
20160184320 | BIOAVAILABLE SOLID STATE (17-SS;)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS - Disclosed are bioavailable solid state (17-β)-Hydroxy-4-Androsten-3-one esters suitable for pharmaceutical uses and administration to mammals in need of (17-β)-Hydroxy-4-Androsten-3-one. | 2016-06-30 |
20160184321 | COMPOSITIONS AND THEIR USE IN ORAL DOSING REGIMENS - Described herein are oral pharmaceutical compositions and their use in testosterone replacement therapy applications. | 2016-06-30 |
20160184322 | USE OF ent-PROGESTERONE TO BETTER OUTCOMES ASSOCIATED WITH TBI AND mTBI - The present invention relates to prophylactic and post-acute treatments of mild TBI (including concussions). | 2016-06-30 |
20160184323 | PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF - Pharmaceutical compositions for intraocular injection are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), at least one pharmaceutically acceptable excipient and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them for intraocular injections are also described. | 2016-06-30 |
20160184324 | PHARMACEUTICAL COMPOSITION AND METHODS - Disclosed herein are compositions having a lipophilic active agent and methods of their use. | 2016-06-30 |
20160184325 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS - The invention provides, in part, polyhydroxylated bile acids for treating biliary disorders, for example, biliary disorders arising out of cholestasis of portal hypertension. The invention also provides, in part, polyhydroxylated bile acids for stimulating bile flow. New compounds 2α, 3α, 7α, 12α-tetrahydroxy-5β-cholanoic acid and 3α, 4α, 7α, 12α-tetrahydroxy-5β-cholanoic acid are disclosed, uses thereof and synthesis thereof. | 2016-06-30 |
20160184326 | Nutritional Intervention for Improving Muscular Function and Strength - The present invention provides a composition comprising HMB and Vitamin D. Methods of administering HMB and Vitamin D to an animal are also described. Vitamin D and HMB are administered to increase muscle mass, strength, and functionality. The combination of Vitamin D and HMB together has a synergistic effect, which results in a surprising and unexpected level of improvement in muscle mass, strength and functionality. | 2016-06-30 |
20160184327 | USE OF 2-METHYLENE-19-NOR-(20S)-1-ALPHA,25-DIHYDROXYVITAMIN D3 TO TREAT PRIMARY HYPERPARATHYROIDISM - Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D | 2016-06-30 |
20160184328 | USE OF 2-METHYLENE-19-NOR-(20S)-1-ALPHA,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM IN PATIENTS PREVIOUSLY TREATED WITH CALCIMIMETICS - Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D | 2016-06-30 |
20160184329 | Formulations and Compositions of Vitamin D Analogs for Treating and Preventing Cancer and other Diseases - This invention is for formulations of analogs of the non-toxic and inert Vitamin D3, its non-toxic and mostly inert pre-hormone and its toxic and biologically active hormone, and for using these formulations for preventing and treating certain cancers such as breast, prostate, ovarian, kidney, renal and other cancers, Vitamin D deficiency, autoimmune disease such as Multiple Sclerosis, hypertension, osteoporosis, bone diseases, rickets, psoriasis and infectious diseases. This invention also discloses compositions of the analogs of the non-toxic and inert Vitamin D3 and the non-toxic and mostly inert Vitamin D3 pre-hormone. | 2016-06-30 |
20160184330 | Suppression of Cytokine Release and Cytokine Storm - The present invention includes methods and compositions for ameliorating symptoms or treating one or more adverse reactions triggered by infectious diseases or disease conditions that trigger a widespread release of cytokines in a subject comprising the steps of: identifying the subject in need of amelioration of symptoms or treatment of the infectious diseases or disease conditions that trigger a widespread release of cytokines; and administering one or more pharmaceutical compositions comprising a therapeutically effective amount of a curcumin extract, curcuminoids or synthetic curcumin (S-curcumin) and derivatives thereof, or empty liposomes, dissolved or dispersed in a suitable aqueous or non-aqueous medium sufficient to reduce the level of cytokines in the host. | 2016-06-30 |
20160184331 | BASE AND EXTERNAL PREPARATION FOR SKIN - An object of the present invention is to provide: a novel base that, after application to a skin surface, can rapidly form a coating film and moreover mitigates skin irritation and occurrence of odors; and an external preparation for skin. The base is used in an external preparation for skin that administers an active ingredient transdermally, and is characterized by containing at least an acrylic-based synthetic polymer and a volatile oil, wherein the base is in a liquid or ointment form prior to application to the skin surface, and the volatile oil evaporates after application of the base to form a hydrophobic coating film containing the volatile oil in the range of 0 to 60 wt % with respect to 100 parts by weight of the acrylic-based synthetic polymer. | 2016-06-30 |
20160184332 | MEDICAMENT COMPRISING A PHARMACEUTICAL COMBINATION OF DRUGS - The present invention concerns a pharmaceutical combination comprising (a) dolutegravir, (b) emtricitabine and (c) tenofovir or a prodrug thereof, wherein preferably the compounds are present in a specific weight ratio and/or in specific amounts, for use as a medicament, preferably in treatment of viral infection/disease such as an HIV infection. Further, the present invention relates to a pharmaceutical composition comprising the pharmaceutical combination and optionally further pharmaceutical excipient(s). | 2016-06-30 |
20160184333 | MITOCHONDRIA-TARGETED ANTI-TUMOR AGENTS - Described are mitochondria-targeted anti-tumor agents, and methods of making and using the same for the treatment of disorders associated with unwanted cell proliferation. | 2016-06-30 |
20160184334 | BORON-CONTAINING SMALL MOLECULES - This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate. | 2016-06-30 |
20160184335 | ANTITUMOR AGENT - The objective of the present invention is to provide a highly safe antitumor agent having excellent antitumor activity and few side effects. The antitumor agent of the present invention is characterized in that it contains cellobiose as an active ingredient. | 2016-06-30 |
20160184336 | ESTERS OF 2-DEOXY-MONOSACHARIDES WITH ANTI PROLIFERATIVE ACTIVITY - Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed. | 2016-06-30 |
20160184337 | METHOD FOR TREATING OBESITY - The present invention is directed to methods for treating obesity, reducing excessive body weight, treating an obesity-related condition, treating unwanted localized fat deposits, and treating areas of cellulite. The method comprises the steps of first identifying a subject in need thereof, and administering to the subject an effective amount of rhamnolipids. A pharmaceutical composition comprising rhamnolipids can be applied by any accepted mode of administration including oral, intranasal, subcutaneous, percutaneous, intravenous, or intracutaneous administration. | 2016-06-30 |
20160184338 | Bioactive Alkaloid Compositions and Their Medical Uses - The present invention relates to a novel alkaloid and novel bioactive alkaloid fractions derivable from | 2016-06-30 |
20160184339 | Compounds, Compositions and Methods Using E-Selectin Antagonists for Mobilization of Hematopoietic Cells - Methods are provided herein for use of E-selectin antagonists for mobilizing cells, such as hematopoietic cells, hematopoietic stem cells and progenitor cells, white blood cells, and malignant cells, and hematopoietic tumor cells from the bone marrow. More specifically, methods are provided for using E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers, and peptides for mobilizing cells from the bone marrow to the peripheral vasculature and tissues. | 2016-06-30 |
20160184340 | THE USE OF SPINOSYNS AND SPINOSYN COMPOSITIONS AS LOCAL ANESTHETICS AND AS ANTIARRHYTHMIC AGENTS - The present invention relates to the use of spinosyns and spinosyn compositions as local anesthetics and antiarrhythmic agents. Advantageously, spinosyns may be used as local anesthetics and/or antiarrhythmic agents with little or no disruption or harm to the host which may be an animal or human. | 2016-06-30 |
20160184341 | ORAL ADMINISTRATION OF ANTHOCYANINS, ANTHOCYANIDINS, AND THEIR METABOLITES FOR THE TREATMENT OF INFLAMMATION IN AN INFLAMMED JOINT - The invention provides methods of reducing inflammation and improving the catabolic/anabolic state to promote healing of the cartilage in a joint by providing an oral dosage of either an anthocyanin or an anthocyanidin or their metabolites or a combination thereof. The treatment can occur before surgery, injury or inflammation occurs as a prophylactic treatment and/or can continue during or after the surgery, injury or inflammation has begun. | 2016-06-30 |
20160184342 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA WITH IVERMECTIN - Methods for safe and effective treatment of inflammatory lesions of rosacea in a subject are described. The methods involve once daily topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. It has been demonstrated that once daily topical treatment with ivermectin is significantly superior than twice-daily topical treatment with metronidazole in reducing inflammatory lesion counts. | 2016-06-30 |
20160184343 | THERAPEUTICAL BETA-GLUCAN COMPOSITION, MODULATING HUMAN IMMUNE SYSTEM AND INITIATING THE BREAKDOWN OF CANCEROUS CELLS - This invention relates to the field of biotechnology. It describes organism immunostimulation, initiation of breakdown processes of cancerous cells and prevention of the formation of metastases, using water soluble β-glucan compositions of various molecular masses. In this invention is also described unique biocatalyst produced by | 2016-06-30 |
20160184344 | STIMULI RESPONSIVE COMPOSITIONS FOR IRON CHELATION - The present technology provides new compositions comprising at least one cross-linked co-polymer. In some embodiments, the polyacrylamide co-polymer comprises water soluble subunits, cross-linking subunits, and iron chelating subunits. In other embodiments, the co-polymer comprises water soluble units, cross-linking subunits, and substituted subunits, which can be conjugated with iron-chelating agents. When these new particles are exposed to certain environments, such the presence of strong acids or oxidation agents, these particles are capable of breaking up so that the iron chelating agents can chelate iron or other metals from their environments. Methods to prepare these new compositions are also provided. These compositions or compositions comprising nanogels of the present technology may be used to treat metal overload conditions such as iron overload resulting from chronic transfusions. | 2016-06-30 |
20160184345 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF - One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor. | 2016-06-30 |
20160184346 | ANTISEPTIC COMPOSITIONS AND METHODS - A skin antisepsis composition comprising a vehicle comprising a (C1-4)alcohol and water in a ratio of at least 60:40, a hydroxycarboxylic acid, a cationic film-forming polymer, and at least one antimicrobial agent; and methods of using the composition are provided. | 2016-06-30 |
20160184347 | MEDICINE FOR PREVENTING OR SUPPRESSING ENGRAFTMENT OF CANCER CELLS INCLUDING AN ORGANIC ACID POLYMER AS ACTIVE INGREDIENT - Pharmaceutical uses of an organic acid polymer, specifically a 3-oxygermylpropionic acid polymer. | 2016-06-30 |
20160184348 | BLOOD CIRCULATION PROMOTING EXTERNAL PREPARATION CONTAINING CARBONATED WATER, BLOOD CIRCULATION PROMOTING DEVICE FOR THE PREPARATION, AND BLOOD CIRCULATION PROMOTING METHOD USING THE PREPARATION - Provided is a blood circulation promoting external preparation containing carbonated water which is applied to a target site of a living body together with ultrasonic irradiation. | 2016-06-30 |
20160184349 | Citrate Containing Beverage - Provided are beverage compositions comprising a urine citrate increasing component and a urine oxalate reducing component. The beverage compositions may be provided in a ready-to-drink form or may be provided in a concentrate form. Also provided are kits comprising the beverage compositions and methods for treating various conditions using the beverage compositions. | 2016-06-30 |
20160184350 | DIALYSIS PRECURSOR COMPOSITION - A dialysis acid precursor assembly including: a dry dialysis acid precursor composition including sodium chloride, a dry acid and a magnesium chloride 4.5-hydrate (MgCl2.4.5H2O), a calcium salt and at least one of a potassium salt, calcium salt and an anhydrous glucose, and a moisture-resistant container having a water vapor transmission rate less than 0.2 g/m2/d at 38° C./90% RH, wherein the dry dialysis acid precursor composition is sealed in the container. | 2016-06-30 |
20160184351 | NEW COMPOSITION TO TREAT INFLAMMATION - A composition for treating inflammation in a patient by administering within an exudate of the patient, which composition includes a concentration of less than or equal to 125 mM of one or more active ingredients salt for treating one or more symptoms of such inflammation, preferably less than or equal to 100 mM, and particularly preferably less than or equal to 75 mM. | 2016-06-30 |